Comparing Biosimilars and Reference Biologics for Inflammatory Diseases in China
Author Information
Author(s): Du Xin, Luo Xingxian, Guo Qixiang, Jiang Xiaomeng, Su Ziling, Zhou Weiting, Wang Zhongjian, Li Jiarun, Yang Yue, Zhang Yi
Primary Institution: Vanke School of Public Health, Tsinghua University, Beijing, China
Hypothesis
This study aims to assess the clinical benefits, cost, and uptake of biosimilars compared to reference biologics in patients with immune-mediated inflammatory diseases in China.
Conclusion
IMID biosimilars in China provide clinical benefits comparable to their reference biologics and offer significant cost savings.
Supporting Evidence
- Biosimilars demonstrated comparable safety and efficacy to reference biologics in multiple studies.
- Patients using biosimilars could save between $874 and $2,184 per month.
- Uptake rates for biosimilars ranged from 16.5% to 72.1% in China.
- Simulation showed significant potential savings with 100% biosimilar substitution.
Takeaway
Biosimilars are cheaper versions of expensive drugs that work just as well, helping more people get the treatment they need.
Methodology
The study analyzed 12 RCTs and cohort studies comparing biosimilars to reference drugs, assessing efficacy, safety, and cost.
Potential Biases
Some studies had uncertain risk of bias, and the absence of real-world data may affect the findings.
Limitations
The study's generalizability is limited due to the lack of real-world evidence from China and reliance on published data.
Participant Demographics
The study included a total of 5,717 patients with IMIDs, with varying demographics across the included studies.
Statistical Information
P-Value
0.33
Confidence Interval
95% CrI, 0.99–1.06
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website